Try our beta test site
30 studies found for:    United States, Indiana | Community Regional Cancer Care
Show Display Options
Rank Status Study
21 Recruiting NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma
Conditions: Advanced Malignant Neoplasm;   Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Plasma Cell Myeloma;   Refractory Malignant Neoplasm;   Refractory Plasma Cell Myeloma
Interventions: Drug: Afatinib;   Drug: Akt inhibitor AZD5363;   Drug: Binimetinib;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dasatinib;   Drug: Defactinib;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab Emtansine;   Drug: Trk Inhibitor LOXO-101;   Drug: Vismodegib;   Drug: WEE1 Inhibitor AZD1775
22 Recruiting Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma
Interventions: Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: photon beam radiation therapy;   Radiation: proton beam radiation therapy;   Drug: temozolomide;   Other: laboratory biomarker analysis
23 Recruiting Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
Conditions: Stage IB Breast Cancer;   Stage II Breast Cancer
Interventions: Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
24 Active, not recruiting S1202: Duloxetine Hydrochloride to Treat Muscle, Bone, and Joint Pain in Pts W/Early-Stage Breast Cancer Receiving Hormone Therapy
Conditions: Breast Cancer;   Musculoskeletal Complications;   Pain
Interventions: Drug: duloxetine hydrochloride;   Other: placebo
25 Active, not recruiting Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Conditions: Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Biological: Trastuzumab
26 Active, not recruiting
Has Results
Temozolomide (TMZ) and Radiation Therapy (RT) With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Cognitive Side Effects of Cancer Therapy
Interventions: Radiation: Radiation therapy pre-randomization;   Biological: Bevacizumab;   Drug: Placebo;   Drug: Temozolomide pre-randomization;   Drug: Temozolomide post-randomization;   Radiation: Radiation therapy post-randomization
27 Active, not recruiting
Has Results
Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
Conditions: Estrogen Receptor Positive;   HER2 Positive Breast Carcinoma;   HER2/Neu Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Fulvestrant;   Other: Laboratory Biomarker Analysis;   Drug: Lapatinib Ditosylate;   Other: Placebo
28 Active, not recruiting Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
Conditions: Breast Adenocarcinoma;   Estrogen Receptor and/or Progesterone Receptor Positive;   HER2/Neu Negative;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIB Breast Cancer
Interventions: Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Tamoxifen Citrate
29 Active, not recruiting
Has Results
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
Conditions: Estrogen Receptor Positive Breast Cancer;   Progesterone Receptor Positive Tumor;   Recurrent Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer
Interventions: Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Procedure: Oophorectomy;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Tamoxifen;   Drug: Triptorelin
30 Active, not recruiting S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy
Condition: Breast Cancer
Intervention: Drug: chemotherapy

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-30) Next Page   
Study has passed its completion date and status has not been verified in more than two years.